BridgeBio price target raised to $45 from $42 at BofA
BofA raised the firm’s price target on BridgeBio (BBIO) to $45 from $42 and keeps a Buy rating on the shares after the company announced the FDA approved its stabilizer acoramidis as Attruby for ...
Monthly Prescribing Reference12h
Attruby Approved for Cardiomyopathy of Transthyretin-Mediated Amyloidosis
The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...
The American Journal of Managed Care14h
FDA Approves Acoramidis for ATTR-CM
With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete ...
WebMD14h
FDA Approves New Drug for Life-Threatening Heart Condition
The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...
TCTMD18h
FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy
Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.
Hosted on MSN20h
BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...
BridgeBio’s Attruby Gains FDA Approval, Boosting Market Potential and Analyst Confidence with Buy Rating
Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on BridgeBio Pharma (BBIO – Research Report) yesterday and set a ...
BridgeBio Pharma’s Promising Prospects: FDA Approval of Attruby and Strategic Pricing Bolster Buy Rating
In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...
Managed Healthcare Executive20h
FDA Approves Attruby for Hearth Failure Indication
Attruby (acoramidis) is a small molecule approved to treat adults with transthyretin amyloid cardiomyopathy. It will have a ...
GEN20h
Bridgebio’s Attruby, to Treat Heart Condition ATTR-CM, Receives FDA Approval
Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...
US FDA approves BridgeBio's drug for rare heart condition (Nov 22)
(In Nov. 22 story, corrects list price of Pfizer's drug to about $268,000 from $225,000 in paragraph 3) (Reuters) -The U.S.